严重创伤患者腔静脉滤器的多中心试验
这项多中心随机对照试验纳入240例损伤严重度评分>15且存在抗凝禁忌的严重创伤患者,随机分为入院72小时内放置腔静脉滤器组与不放置滤器组。主要终点为入组后90天症状性肺栓塞或全因死亡的复合终点,滤器组13.9% vs 对照组14.4%(HR 0.99,95%CI 0.51–1.94,P=0.98),差异无统计学意义。在伤后7天内未接受预防性抗凝的亚组中,滤器组46例无肺栓塞发生,对照组34例中5例(14.7%)发生肺栓塞(相对风险0,95%CI 0.00–0.55),其中1例死亡。结论为严重创伤后早期预防性放置腔静脉滤器未降低90天症状性肺栓塞或死亡发生率。
要点
- 严重创伤(损伤严重度评分>15)且存在抗凝禁忌的患者,早期(入院72小时内)放置腔静脉滤器 vs 不放置,90天症状性肺栓塞或全因死亡复合终点为13.9% vs 14.4%(HR 0.99,95%CI 0.51–1.94,P=0.98),无显著差异。
- 在伤后7天内未接受预防性抗凝的亚组中,滤器组46例无肺栓塞发生,对照组34例中5例(14.7%)发生肺栓塞(相对风险0,95%CI 0.00–0.55),其中1例死亡。
- 滤器组6例患者滤器内发现捕获血栓。
- 所有患者在2周时接受下肢超声检查,符合预设标准时接受强制性CT肺动脉造影。
- 研究结论:严重创伤后早期预防性放置腔静脉滤器未降低90天症状性肺栓塞或死亡发生率。
适用人群与场景
- 严重创伤患者,损伤严重度评分>15(评分范围0–75,评分越高损伤越严重),且存在抗凝药物禁忌,入住后72小时内入组。
诊断标准与关键阈值
- 损伤严重度评分>15分且存在抗凝药物禁忌。
- 主要终点:入组后90天症状性肺栓塞或全因死亡的复合终点。
- 次要终点:存活至少7天且伤后7天内未接受预防性抗凝的亚组中,第8天至第90天之间的症状性肺栓塞。
处置流程与药物剂量
- 腔静脉滤器组在入院后72小时内放置腔静脉滤器。
- 对照组不放置滤器。
- 所有患者在2周时接受下肢超声检查;符合预设标准时接受强制性CT肺动脉造影。
研究设计与关键结果
- 多中心随机对照试验,纳入240例严重创伤(损伤严重度评分>15)且存在抗凝禁忌的患者,随机分为入院72小时内放置腔静脉滤器组与不放置滤器组。
- 患者中位年龄39岁,中位损伤严重度评分27分。
- 主要终点(90天症状性肺栓塞或全因死亡复合终点):滤器组13.9% vs 对照组14.4%(HR 0.99,95%CI 0.51–1.94,P=0.98),无显著差异。
- 亚组分析:伤后7天内未接受预防性抗凝的患者中,滤器组46例无肺栓塞发生,对照组34例中5例(14.7%)发生肺栓塞(相对风险0,95%CI 0.00–0.55),其中1例死亡。
- 滤器组6例患者滤器内发现捕获血栓。
证据类型、等级与局限
- 证据类型:多中心随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于严重创伤(损伤严重度评分>15)且存在抗凝禁忌的患者,早期预防性放置腔静脉滤器未降低90天症状性肺栓塞或死亡发生率,不支持以降低该复合终点为目的常规早期放置滤器。
- 在伤后7天内未接受预防性抗凝的亚组中,滤器组无肺栓塞发生而对照组有5例(14.7%)发生肺栓塞(相对风险0,95%CI 0.00–0.55),提示该亚组可能获益,但需注意该亚组样本量小(滤器组46例、对照组34例)。
- 滤器组6例患者滤器内发现捕获血栓,放置滤器后需关注滤器内血栓形成。
指南或共识出处
- Australian New Zealand Clinical Trials Registry number, ACTRN12614000963628
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Whether early placement of an inferior vena cava filter reduces the risk of pulmonary embolism or death in severely injured patients who have a contraindication to prophylactic anticoagulation is not known.
METHODS: In this multicenter, randomized, controlled trial, we assigned 240 severely injured patients (Injury Severity Score >15 [scores range from 0 to 75, with higher scores indicating more severe injury]) who had a contraindication to anticoagulant agents to have a vena cava filter placed within the first 72 hours after admission for the injury or to have no filter placed. The primary end point was a composite of symptomatic pulmonary embolism or death from any cause at 90 days after enrollment; a secondary end point was symptomatic pulmonary embolism between day 8 and day 90 in the subgroup of patients who survived at least 7 days and did not receive prophylactic anticoagulation within 7 days after injury. All patients underwent ultrasonography of the legs at 2 weeks; patients also underwent mandatory computed tomographic pulmonary angiography when prespecified criteria were met.
RESULTS: The median age of the patients was 39 years, and the median Injury Severity Score was 27. Early placement of a vena cava filter did not result in a significantly lower incidence of symptomatic pulmonary embolism or death than no placement of a filter (13.9% in the vena cava filter group and 14.4% in the control group; hazard ratio, 0.99; 95% confidence interval [CI], 0.51 to 1.94; P = 0.98). Among the 46 patients in the vena cava filter group and the 34 patients in the control group who did not receive prophylactic anticoagulation within 7 days after injury, pulmonary embolism developed in none of those in the vena cava filter group and in 5 (14.7%) in the control group, including 1 patient who died (relative risk of pulmonary embolism, 0; 95% CI, 0.00 to 0.55). An entrapped thrombus was found in the filter in 6 patients.
CONCLUSIONS: Early prophylactic placement of a vena cava filter after major trauma did not result in a lower incidence of symptomatic pulmonary embolism or death at 90 days than no placement of a filter. (Funded by the Medical Research Foundation of Royal Perth Hospital and others; Australian New Zealand Clinical Trials Registry number, ACTRN12614000963628.).
参考来源
- Ho KM, Rao S, Honeybul S, et al. A Multicenter Trial of Vena Cava Filters in Severely Injured Patients. N Engl J Med. 2019. PMID: 31259488. doi:10.1056/NEJMoa1806515
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。